Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Diagnosis and treatment marker of prostate cancer

A technology of prostate cancer and markers, which is applied in the field of diagnostic and therapeutic markers of prostate cancer, and can solve problems affecting the effect of tumor treatment

Inactive Publication Date: 2016-11-23
北京致成生物医学科技有限公司
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, chemoradiotherapy drugs not only act on the tumor, but can also act on the healthy tissues around the tumor. Therefore, while killing the tumor, they also bring great side effects to the body, which ultimately affects the therapeutic effect on the tumor.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnosis and treatment marker of prostate cancer
  • Diagnosis and treatment marker of prostate cancer
  • Diagnosis and treatment marker of prostate cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1 High-throughput sequencing screening of differentially expressed genes

[0036] 1. Sampling

[0037] From October 2012 to December 2015, 27 tissue samples were obtained from the Department of Urology at Peking Union Medical College Hospital. All samples were confirmed by pathological examination, including 8 cases of paracancerous tissue samples and 19 cases of prostate cancer samples. Store in -80°C low temperature refrigerator.

[0038] 2. Total RNA extraction from tissue samples

[0039] use Reagent (invitrogen, Cat. No. 15596-018) was used to extract sample RNA, and the experimental operation was carried out according to the product manual. The specific operation was as follows:

[0040] After collecting the samples, freeze them in liquid nitrogen. After taking them out, put the tissue into a pre-cooled mortar for grinding. After the tissue sample is powdered:

[0041] ① Add Trizol and store at room temperature for 5 minutes;

[0042] ② Add 0.2 mL of...

Embodiment 2

[0051] Example 2 RT-PCR verification of the expression of NCRNA00087 in prostate cancer tissues and paracancerous tissues

[0052] 1. Materials

[0053] 20 prostate cancer tissue samples and 8 paracancerous tissue samples were collected from prostate cancer samples during urological surgery in Peking Union Medical College Hospital from 2012 to 2015, and they were grouped and numbered. All samples were confirmed by pathological examination.

[0054] 2. Method

[0055] 2.1 Extract the total RNA from the tissue sample, the same as the extraction method in Example 1.

[0056] 2.2 Synthesis of cDNA by reverse transcription

[0057] use III Reverse Transcriptase (invitrogen, Cat. No. 18080-044) was used for cDNA reverse transcription, and the experimental operation was carried out according to the product manual. The specific operation was as follows:

[0058] Using a reverse transcription kit, 1 μg of total RNA was reverse-transcribed with reverse transcription buffer to synt...

Embodiment 3

[0072] Example 3 RNAi interferes with the expression of NCRNA00087 and its impact on prostate cancer cells

[0073] 1. Materials

[0074] 1. Source of cells

[0075] Prostate cancer PC-3 cell line was purchased from ATCC, USA

[0076] 2. siRNA design and synthesis

[0077] According to the online design software siDirect version 2.0 (http: / / design.rnai.jp / ), according to the gene sequence, refer to NCBI: NR_024493.2 (NCRNA00087), design the corresponding siRNA, the specific sequence is shown in Table 3. After the design is sent to the synthesis company for synthesis.

[0078] Table 3 List of siRNA sequences

[0079]

[0080] 2. Experimental method

[0081] 1. Cell grouping

[0082] Group C: blank control group; Group C1: liposome transfection group; C2 group: non-specific siRNA-NC transfection group; S1, S2 groups: specific siRNA transfection group.

[0083] 2. Transfection

[0084] Follow Lipofectamine TM The steps provided by 2000Transfection Reagent were carried...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a diagnosis and treatment marker of prostate cancer. The marker is NCRNA00087, and the invention further verifies that the expression of the NCRNA00087 in prostate cancer tissues is increased. The invention further discloses a diagnostic kit for detecting the prostate cancer; the kit comprises a primer for specially amplifying prostate cancer-correlated lncRNA (long non-coding RNA) and an instruction; the prostate cancer-correlated lncRNA is the NCRNA00087. The invention further discloses an NCRNA00087 inhibitor; the inhibitor comprises siRNA of the NCRNA00087. When the NCRNA00087 is used for detecting the prostate cancer, early detection can be rapidly and effectively realized, and a therapeutic target point and important evidences are provided for clinical application of gene therapy, pharmaceutical therapy and the like.

Description

technical field [0001] The invention relates to the field of biomedicine, and relates to a diagnosis and treatment marker for prostate cancer, specifically the marker is NCRNA00087. Background technique [0002] Prostate cancer is one of the common male reproductive system malignancies. Worldwide, the incidence of prostate cancer ranks second among all malignant tumors in men. In the United States, the incidence of prostate cancer has surpassed that of lung cancer, becoming the first tumor that endangers men's health. The incidence of prostate cancer in Asia is far lower than that in European and American countries, but it has shown an upward trend in recent years, and the growth rate is faster than that in developed countries in Europe and America. Prostate cancer patients are mainly elderly men, usually after the age of 50, 95% occur in elderly men over 60 years old, and the incidence rate continues to increase with age. Prostate cancer often has no symptoms in the early...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68C12N15/113A61K31/7088A61P35/00
CPCC12Q1/6886A61K31/7088C12Q2600/158C12Q2600/178
Inventor 刘昊
Owner 北京致成生物医学科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com